 WESTLAKE VILLAGE, Calif., Dec. 09, 2020 GLOBE NEWSWIRE -- Arcutis Biotherapeutics, Inc. Nasdaq: ARQT, a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced continued progress and future growth drivers related to its immuno-dermatology platform and pipeline, which will be highlighted during todays Virtual Investor Day at 11:00 am ET. 